Lorbrena/ Lorviqua ( lorlatinib) 100 мг №30 in tab, generic

Lorviqua Indications

It is indicated as first-line therapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC).

It is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after receiving the following agents: alectinib or ceritinib as first-line therapy with ALK tyrosine kinase inhibitors (TKIs); or crizotinib and at least one other ALK TKI.